SeaStar Medical Holding Corporation announces receipt of U.S. Food and Drug Administration Breakthrough Device Designation for its patented, first-in-class, cell-directed Selective Cytopheretic Device for use with patients in the hospital intensive care unit with acute kidney injury and acute on chronic liver failure. This is the third Breakthrough Device Designation granted by the FDA to SeaStar Medical for the SCD device, and is expected to expedite the clinical development and regulatory review of the SCD for use in this patient population.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICU:
- FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
- SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023
- SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
- FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome
- SeaStar Medical announces FDA granted Breakthrough Device Designation for SCD
